AAPL326.59-7.15 (-2.14%) ▼|ABBV253.42-1.07 (-0.42%) ▼|ABT101.70+1.02 (+1.01%) ▲|ACN144.73+1.16 (+0.81%) ▲|ADBE234.74-2.51 (-1.06%) ▼|AMAT525.70-3.96 (-0.75%) ▼|AMD503.57+7.81 (+1.58%) ▲|AMGN364.17-2.12 (-0.58%) ▼|AMT167.06-3.00 (-1.76%) ▼|AMZN249.99+2.76 (+1.12%) ▲|AVGO378.16+7.34 (+1.98%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.41+0.50 (+0.10%) ▲|C128.73-0.63 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.85-32.26 (-2.74%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.76-3.97 (-1.90%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.41-3.09 (-2.42%) ▼|MS210.98-4.52 (-2.10%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.37-5.04 (-3.99%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|AAPL326.59-7.15 (-2.14%) ▼|ABBV253.42-1.07 (-0.42%) ▼|ABT101.70+1.02 (+1.01%) ▲|ACN144.73+1.16 (+0.81%) ▲|ADBE234.74-2.51 (-1.06%) ▼|AMAT525.70-3.96 (-0.75%) ▼|AMD503.57+7.81 (+1.58%) ▲|AMGN364.17-2.12 (-0.58%) ▼|AMT167.06-3.00 (-1.76%) ▼|AMZN249.99+2.76 (+1.12%) ▲|AVGO378.16+7.34 (+1.98%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.41+0.50 (+0.10%) ▲|C128.73-0.63 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.85-32.26 (-2.74%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.76-3.97 (-1.90%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.41-3.09 (-2.42%) ▼|MS210.98-4.52 (-2.10%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.37-5.04 (-3.99%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|
28.3 C
New York
Monday, July 20, 2026

Tag: agency

newssourceFORcompanyinformationcontent1releasesmarket

Ola-Ola brand Authentic Pounded Yam (Iyan) IYANINSTANT recalled due to undeclared milk

OTTAWA, ON, June 26, 2026 /CNW/ - Product: Authentic Pounded Yam (Iyan) IYANINSTANTIssue: Food - Allergen - MilkDistribution: NationalOnlineSee the affected products and product photos...

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

Canada takes action to advance a stronger grid and increase reliable, affordable energy

YELLOWKNIFE, NT, June 26, 2026 /CNW/ - The world is changing rapidly: global trade has been upended, artificial intelligence is scaling at speed, and...

NACCHO Announces Its 2026-2027 Board of Directors

WASHINGTON, June 26, 2026 /PRNewswire/ -- The National Association of County and City Health Officials (NACCHO), the voice of the over 3,300 local health...

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Various Salem Foods brand Ground Spices and Spice Blends recalled due to undeclared wheat, sesame and mustard

OTTAWA, ON, June 26, 2026 /CNW/ - Product: Ground Spices and Spice Blends Issue: Food - Allergen - Wheat Food - Allergen - Sesame seeds...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade...

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar’s Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.

FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health

If finalized, rule would level the playing field between American and foreign businesses 
If finalized, rule would level the playing field between American and foreign businesses

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAgency

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers